Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Add To Watchlist

Recent & Breaking News (NDAQ:EXEL)

Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status

PR Newswire October 18, 2016

16 Stocks Moving In Monday's Pre-Market Session

Benzinga.com October 10, 2016

Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016

Business Wire October 10, 2016

18 Biggest Mid-Day Losers For Friday

Benzinga.com October 7, 2016

InvestorsObserver releases covered-call reports for Exelixis, NXP Semiconductors, Qualcomm, Generac Holdings and US Steel

PR Newswire October 7, 2016

Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress

Business Wire October 7, 2016

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors

Business Wire October 7, 2016

Exelixis and Ipsen to Host Investor and Media Briefing to Discuss Data Presented at the ESMO 2016 Congress

Business Wire October 3, 2016

Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher

Benzinga.com September 29, 2016

Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide

Benzinga.com September 29, 2016

Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations

Benzinga.com September 29, 2016

15 Stocks Moving In Monday's Pre-Market Session

Benzinga.com September 26, 2016

Exelixis Elects Julie Anne Smith to Its Board of Directors

Business Wire September 26, 2016

Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist

Business Wire September 26, 2016

Covered Call reports for FireEye, Barrick Gold Corporation, General Electric, Facebook and Exelixis include trade ideas that offer returns of 20% or more!

PR Newswire September 22, 2016

Stocks Hitting 52-Week Highs

Benzinga.com September 21, 2016

Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress

Business Wire September 20, 2016

12 Biggest Mid-Day Gainers For Wednesday

Benzinga.com September 14, 2016

Stocks Hitting 52-Week Highs

Benzinga.com September 14, 2016

European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

Business Wire September 14, 2016